v3.25.2
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
OPERATING EXPENSES:        
Research and development $ 30,325 $ 29,069 $ 61,205 $ 53,970
General and administrative 12,608 14,253 31,344 27,925
Total operating expenses 42,933 43,322 92,549 81,895
Loss from operations: (42,933) (43,322) (92,549) (81,895)
OTHER INCOME (EXPENSE), NET:        
Fair value change of warrant liabilities (2,540) 0 16,920 0
Benefit from R&D tax credit 4,287 3,709 12,735 6,810
Interest income 1,898 2,408 4,284 4,668
Foreign exchange gains (losses) 2,349 225 4,482 (558)
Interest expense (1,151) (1,112) (2,275) (2,210)
Other (expense) income (176) 167 627 295
Total other income, net 4,667 5,397 36,773 9,005
Loss before income taxes (38,266) (37,925) (55,776) (72,890)
Income tax expense (137) (176) (491) (398)
Net loss $ (38,403) $ (38,101) $ (56,267) $ (73,288)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share) $ (0.41) $ (0.56) $ (0.62) $ (1.11)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share) $ (0.41) $ (0.56) $ (0.62) $ (1.11)
Weighted average ordinary shares outstanding - basic (in shares) 93,341,594 68,371,139 91,278,385 66,296,658
Weighted average ordinary shares outstanding - diluted (in shares) 93,341,594 68,371,139 91,278,385 66,296,658
Other comprehensive loss:        
Foreign exchange translation adjustment $ 1,729 $ 81 $ 1,612 $ 45
Comprehensive loss $ (36,674) $ (38,020) $ (54,655) $ (73,243)